title: Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report.
abstract: Omalizumab is a monoclonal anti-immunoglobulin E antibody used for the treatment of severe perennial allergic asthma. Previous reports have suggested that omalizumab treatment can be associated with the development of eosinophilic granulomatosis with poliangiitis (EGPA) (formerly known as Churg-Strauss syndrome) and an increased risk of malignancy. Long-term risks of omalizumab treatment are not very well defined. Here, we report the case of a 75-year-old woman with concurrent occurrence of EGPA and brain tumor after more than 7 years of omalizumab treatment. The possibility of EGPA should be borne in mind during long-term treatment with omalizumab. Despite the absence of definitive data, an association may also exist between the development of malignancy and omalizumab use.
authors: Pulmonology Department, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey serminborekci@yahoo.com.tr.
authors: S
authors: S
authors: Borekci
authors: Pathology Department, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
authors: O
authors: O
authors: Aydin
authors: Rheumatology Department, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
authors: G
authors: G
authors: Hatemi
authors: Pulmonology Department, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
authors: B
authors: B
authors: Gemicioglu
mesh_terms: D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy*; D015267:Churg-Strauss Syndrome / Q000139:chemically induced* / Q000209:etiology*; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000139:chemically induced* / Q000209:etiology*; D006801:Humans; D000069444:Omalizumab / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000069444:Omalizumab
keywords: Churg-Strauss syndrome; anti-IgE; asthma; eosinophilic granulomatosis with poliangiitis; malignancy; omalizumab